SCHEMBL5624669

SCHEMBL5624669

Clc1cccc(-c2nccn2Cc2nc3ccncc3n2CC2CC2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
TP53 P04637 2/20 0.38
AOC3 Q16853 3/20 0.37
GLP1R P43220 1/20 0.37
KCNH2 Q12809 1/20 0.37
BRD4 O60885 1/20 0.36
MDM2 Q00987 1/20 0.35
PDE6D O43924 1/20 0.35
PDE4A P27815 1/20 0.35
CRHR1 P34998 1/20 0.34
P2RX7 Q99572 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
ALDH1A2 O94788 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALDH2 P05091 1/20 0.34
ALDH3A1 P30838 1/20 0.34
ALDH1A3 P47895 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3070587 0.90 ALOX5 (0.43) CYP11B1CYP11B2GLP1RKCNH2BRD4
SCHEMBL3072697 0.83 PDE4A (0.40) BRD4MDM2PDE6DPDE4AALDH1A1
SCHEMBL3060643 0.80 GRIN2B (0.41) CYP11B1CYP11B2GLP1RKCNH2GRIN1
SCHEMBL5624242 0.78 KCNH2 (0.32) KCNH2MDM2PDE6DPTGER4
SCHEMBL3062901 0.75 TP53 (0.42) CYP11B1CYP11B2TP53GLP1RKCNH2
SCHEMBL3064280 0.75 CYP11B2 (0.48) CYP11B1CYP11B2AOC3GRIN1GRIN2B
SCHEMBL3060392 0.74 TP53 (0.50) TP53BRD4PDE6DGRM2
SCHEMBL3059704 0.73 TP53 (0.42) TP53BRD4ALDH1A1POLBGRM2
SCHEMBL13089101 0.73 KCNH2 (0.38) KCNH2BRD4MDM2ALDH1A1POLB
SCHEMBL3064857 0.73 ALOX5 (0.39) GLP1RKCNH2GRIN2BGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7300945-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2007-11-27 US disclosed
US-20060025425-A1 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025425-A1 Benzimidazole and pyridylimidazole derivatives GABBR1, GABBR2, GABRA2 CYP11B1 77/4885CYP11B2 47/4885TP53 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.